scholarly journals When Is It Appropriate to Use Vasopressin Receptor Antagonists?

2008 ◽  
Vol 19 (6) ◽  
pp. 1054-1058 ◽  
Author(s):  
Ruediger W. Lehrich ◽  
Arthur Greenberg
Keyword(s):  
Vasopressin Receptor ◽  
Receptor Antagonists

ChemInform Abstract: 5-Fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-yl carbonyl)-2-pyridinyl]benzamide (CL-385004) and Analogues as Orally Active Arginine Vasopressin Receptor Antagonists.

ChemInform ◽  
2010 ◽  
Vol 30 (43) ◽  
pp. no-no
Author(s):  
Venkatesan Aranapakam ◽  
J. Donald Albright ◽  
George T. Grosu ◽  
Efren G. Delos Santos ◽  
Peter S. Chan ◽  
...  
Keyword(s):  
Arginine Vasopressin ◽  
Vasopressin Receptor ◽  
Receptor Antagonists ◽  
Orally Active

scholarly journals Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy

2011 ◽  
Vol 2011 ◽  
pp. 1-7 ◽  
Author(s):  
Adam Romanovsky ◽  
Sean Bagshaw ◽  
Mitchell H. Rosner
Keyword(s):  
Heart Failure ◽  
Clinical Trials ◽  
Free Water ◽  
Volume Overload ◽  
Decompensated Heart Failure ◽  
Vasopressin Receptor ◽  
Receptor Antagonists ◽  
Water Excretion ◽  
Multiple Systems ◽  
Developed World

Heart failure is one of the most common chronic medical conditions in the developed world. It is characterized by neurohormonal activation of multiple systems that can lead to clinical deterioration and significant morbidity and mortality. In this regard, hyponatremia is due to inappropriate and continued vasopressin activity despite hypoosmolality and volume overload. Hyponatremia is also due to diuretic use in an attempt to manage volume overload. When hyponatremia occurs, it is a marker of heart failure severity and identifies patients with increased mortality. The recent introduction of specific vasopressin-receptor antagonists offers a targeted pharmacological approach to these pathophysiological derangements. Thus far, clinical trials with vasopressin-receptor antagonists have demonstrated an increase in free-water excretion, improvement in serum sodium, modest improvements in dyspnea but no improvement in mortality. Continued clinical trials with these agents are needed to determine their specific role in the treatment of both chronic and decompensated heart failure.

Vasopressin-receptor antagonists in heart failure

2008 ◽  
Vol 65 (9) ◽  
pp. 807-817 ◽  
Author(s):  
Teresa A. Schweiger ◽  
Martin M. Zdanowicz
Keyword(s):  
Heart Failure ◽  
Vasopressin Receptor ◽  
Receptor Antagonists

Pyrazinobenzodiazepines as Potent Nonpeptide Vasopressin Receptor Antagonists

2005 ◽  
Vol 2 (3) ◽  
pp. 219-223 ◽  
Author(s):  
Jay Matthews ◽  
Dennis Hlasta ◽  
Patricia Andrade-Gordon ◽  
Keith Demarest ◽  
Eric Ericson ◽  
...  
Keyword(s):  
Vasopressin Receptor ◽  
Receptor Antagonists

Corrigendum to “Bridged bicyclic vasopressin receptor antagonists with V2-selective or dual V1a/V2 activity”

2004 ◽  
Vol 14 (12) ◽  
pp. 3363 ◽  
Author(s):  
Alexey B. Dyatkin ◽  
William J. Hoekstra ◽  
Dennis J. Hlasta ◽  
Patricia Andrade-Gordon ◽  
Lawrence de Garavilla ◽  
...  
Keyword(s):  
Vasopressin Receptor ◽  
Receptor Antagonists
Sign in / Sign up

Export Citation Format

Share Document